Objective: To test the theoretical utility of incorporating nonavalent vaccination against HPV into a clinical setting.
| INTRODUCTION
HPV is a DNA virus associated with precancerous conditions of the lower genital tract. Approximately 27 000 cases of HPV-related cancers occur each year in the USA. 1, 2 More than 100 HPV types are known, and more than 40 types can be spread through sexual contact.
In particular, it is estimated that HPV16 and HPV18 are the most common HPV types involved in the genesis of genital cancers, being involved in more than 70% of cervical cancer.
1,2
HPV vaccines can prevent the most common types of infections. 
| MATERIALS AND METHODS
In the present retrospective study, records from consecutive women who underwent HPV-DNA test between January 1, 1998, and HPV testing was performed using the Clinical Array Technology HPV 2 assay (CLART; Genomica, Madrid, Spain), which combines highly specific and sensitive PCR with low-density array technology.
Details regarding HPV testing have been reported elsewhere.
17
To assess changes in the prevalence of HPV types over time, the study duration was stratified into three periods, denoted as T1 
| RESULTS
Over the whole study period, 13 665 patients participated in screening. The mean ± SD age was 43. 
| DISCUSSION
The present study investigated trends in HPV-type prevalence and reported several noteworthy findings. First, it was observed that, 
